Pharma patent wars: Congress caps litigation harassment against generics
H.R. 3269 — ETHIC Act · Filed by Jodey Arrington (R-TX) · 9 cosponsors · Introduced May 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill limits pharmaceutical and biological product makers to asserting only one patent per 'Patent Group' (a cluster of related patents linked by USPTO disclaimers) in any single infringement lawsuit against generic drug applicants or biosimilar makers. It prevents patent holders from filing multiple lawsuits against the same generic/biosimilar competitor using different patents from the same group, reducing litigation harassment and lowering barriers to market entry for cheaper alternatives.
Why we flagged it
The bill directly addresses patent thickets—a well-documented anticompetitive practice in pharmaceutical litigation—by constraining how many related patents a single patent holder can assert in one lawsuit. It is a targeted procedural reform, not a broad deregulation or subsidy.
What the text implies
- Patent holders may respond by filing separate lawsuits against the same generic/biosimilar competitor using different Patent Groups, potentially shifting litigation burden rather than reducing it.
- The definition of 'Patent Group' depends on USPTO disclaimer practices under 35 U.S.C. § 253; changes to disclaimer rules or interpretation could alter the scope of the restriction.
- Applies only to drug and biological product litigation; does not affect patent thicket tactics in other industries (software, hardware, telecommunications).
- May incentivize patent holders to structure patent portfolios differently to avoid disclaimer linkages, creating new strategic behavior.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Generic and biosimilar drugs reach patients faster and at lower cost when patent holders cannot weaponize overlapping patent portfolios to delay market entry through serial litigation. Consumers and public health systems benefit from reduced drug prices and faster generic/biosimilar availability.
Who stands to gain
- generic pharmaceutical manufacturers
- biosimilar manufacturers
- pharmacy benefit managers
- health insurance companies
Named in the bill
35 U.S.C. § 271(e), 35 U.S.C. § 253, Federal Food, Drug, and Cosmetic Act § 505, Public Health Service Act § 351(k), USPTO, generic drug applicants, biosimilar manufacturers
Where it stands
9 cosponsors: 6 Democrats, 3 Republicans.
- May 8, 2025 — Introduced · Congress.gov: “Introduced in House”
- May 8, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
31 lobbying clients named this bill on 102 disclosure filings across 7 quarters, Mar 2025 to Sep 2026. Those filings disclosed $161,809,030 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 98% of bills with at least one filing.
Jodey Arrington, the sponsor, reported $573,000 in PAC receipts in the 2026 cycle. $5,000 of that came from 2 PACs tied to these lobbying clients.
- Pharmaceutical Research and Manufacturers of America — $51,630,000 on 6 filings
- Chamber of Commerce of the U.S.A. — $33,430,000 on 2 filings
- Amgen Inc — $11,720,000 on 4 filings
- Johnson & Johnson Services Inc — $11,160,000 on 5 filings
- Novartis — $9,800,000 on 6 filings
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,509 characters) on Sep 26, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
- H.R. 3269 on Congress.gov
- Actions and status history
- Cosponsors (9)
- Bill text the analysis read
- Pharmaceutical Research and Manufacturers of America — LDA filing, 2026 Q1
- Chamber of Commerce of the U.S.A. — LDA filing, 2026 Q2
- Amgen Inc — LDA filing, 2025 Q4
- Jodey Arrington — FEC candidate receipts, 2026 cycle
“Pharma patent wars: Congress caps litigation harassment against generics” QuorumCivic. https://share.quorumcivic.app/bill/119/hr3269 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.